GLYCEMIC CONTROL AND CARDIOVASCULAR OUTCOMES IN DIABETIC PATIENTS: A PRIMARY CARE SETTING STUDY
Main Article Content
Keywords
Type 2 diabetes, glycemic control, cardiovascular outcomes, primary care, India
Abstract
Introduction: Type 2 diabetes mellitus is a growing health crisis in India, with cardiovascular disease as a leading cause of morbidity and mortality. This study investigated the relationship between glycemic control and cardiovascular outcomes in patients with type 2 diabetes managed in primary care settings.
Methods: A prospective cross sectional study was conducted across a network of primary care centers. 1,200 adults with type 2 diabetes were followed for 6 months. Glycemic control was categorized based on HbA1c levels. Cox proportional hazards models assessed the relationship between glycemic control and cardiovascular events. Logistic regression identified factors associated with achieving glycemic targets.
Results: Only 27% of patients achieved the target HbA1c of <7.0%. Patients with poor glycemic control (HbA1c ≥9.0%) had a nearly three-fold higher risk of cardiovascular events compared to those with well-controlled diabetes (HR 2.87, 95% CI 1.71-4.82, p<0.001). Factors associated with better glycemic control included older age, female gender, shorter diabetes duration, lower BMI, high medication adherence, metformin use, and regular physical activity. Low medication adherence was associated with a three-fold increase in cardiovascular risk compared to high adherence.
Conclusion: This study highlights the significant association between glycemic control and cardiovascular outcomes in primary care settings. The findings underscore the need for comprehensive, patient-centered approaches to diabetes management that address multiple risk factors and barriers to care, particularly medication adherence.
References
2. ADVANCE Collaborative Group. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 358(24), 2560-2572.
3. American Diabetes Association. (2022). Standards of medical care in diabetes—2022. Diabetes Care, 45(Supplement 1), S1-S264.
4. Anjana, R. M., Deepa, M., Pradeepa, R., Mahanta, J., Narain, K., Das, H. K., ...& Mohan, V. (2017). Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study. The Lancet Diabetes & Endocrinology, 5(8), 585-596.
5. Blonde, L., Aschner, P., Bailey, C., Ji, L., Leiter, L. A., &Matthaei, S. (2017). Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diabetes and Vascular Disease Research, 14(3), 172-183.
6. Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., ...&Tuomilehto, J. (2020). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 41(2), 255-323.
7. Deepa, M., Bhansali, A., Anjana, R. M., Pradeepa, R., Joshi, S. R., Joshi, P. P., ...& Mohan, V. (2014). Knowledge and awareness of diabetes in urban and rural India: The Indian Council of Medical Research India Diabetes Study (Phase I): Indian Council of Medical Research India Diabetes 4. Indian Journal of Endocrinology and Metabolism, 18(3), 379.
8. Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., ...& Huang, G. D. (2009). Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine, 360(2), 129-139.
9. Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018). Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular Diabetology, 17(1), 1-19.
10. Ghosh, A., Arora, B., Gupta, R., Anoop, S., &Misra, A. (2020). Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in north India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14(5), 917-920.
11. Gujral, U. P., Pradeepa, R., Weber, M. B., Narayan, K. V., & Mohan, V. (2013). Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Annals of the New York Academy of Sciences, 1281(1), 51-63.
12. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359(15), 1577-1589.
13. Huffman, M. D., Prabhakaran, D., Abraham, A. K., Krishnan, M. N., Nambiar, A. C., &Mohanan, P. P. (2013). Optimal in-hospital and discharge medical therapy in acute coronary syndromes in Kerala: results from the Kerala acute coronary syndrome registry. Circulation: Cardiovascular Quality and Outcomes, 6(4), 436-443.
14. Indian Council of Medical Research. (2018). ICMR Guidelines for Management of Type 2 Diabetes 2018. New Delhi: ICMR.
15. International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th edition. Brussels, Belgium: International Diabetes Federation.
16. Mohan, V., Anjana, R. M., Pradeepa, R., &Unnikrishnan, R. (2018). Type 2 diabetes in India: Challenges and possible solutions. Global Health, Epidemiology and Genomics, 3, e8.
17. Patel, S. A., Dhillon, P. K., Kondal, D., Jeemon, P., Kahol, K., Manimunda, S. P., ... &Prabhakaran, D. (2016). Chronic disease concordance within Indian households: A cross-sectional study. PLoS medicine, 13(9), e1002127.
18. Unnikrishnan, R., Anjana, R. M., Deepa, M., Pradeepa, R., Joshi, S. R., Bhansali, A., ...& Mohan, V. (2014). Glycemic control among individuals with self-reported diabetes in India—the ICMR–INDIAB Study. Diabetes Technology & Therapeutics, 16(9), 596-603.
19. Venkataraman, K., Kannan, A. T., Kalra, O. P., Gambhir, J. K., Sharma, A. K., Sundaram, K. R., & Mohan, V. (2012). Diabetes self-efficacy strongly influences actual control of diabetes in patients attending a tertiary hospital in India. Journal of Community Health, 37(3), 653-662.
20. Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., ... &Sabatine, M. S. (2019). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet, 393(10166), 31-39.